Mineralys Therapeutics (MLYS) is down -13.9%, or -$6.14 to $38.15.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics price target raised to $56 from $52 at H.C. Wainwright
- Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook
- Mineralys Therapeutics Reports Q3 2025 Financial Results
- Mineralys Therapeutics files automatic mixed securities shelf
- Mineralys Therapeutics reports Q3 EPS (52c), consensus (61c)